OBM Genetics is an international Open Access journal published quarterly online by LIDSEN Publishing Inc. It accepts papers addressing basic and medical aspects of genetics and epigenetics and also ethical, legal and social issues. Coverage includes clinical, developmental, diagnostic, evolutionary, genomic, mitochondrial, molecular, oncological, population and reproductive aspects. It publishes research articles, reviews, communications and technical notes, etc. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Indexing: DOAJ-Directory of Open Access Journals.
Archiving: full-text archived in CLOCKSS.
Rapid publication: manuscripts are undertaken in 8.5 days from acceptance to publication (median values for papers published in this journal in the first half of 2019, 1-2 days of FREE language polishing time is also included in this period).
Molecular Cancer Therapeutics
Submission Deadline: May 01, 2019 (Open)
Tapan K Bera, PhD
Senior Associate Scientist, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Website | E-Mail
Research Interests: antibody engineering; immunotherapy; recombinant immunotoxin; multiple myeloma; BCMA; mesothelin
About This Topic
Molecular Cancer Therapeutics is a special issue focused on articles related to the molecular basis of cancer, discovery and preclinical development of novel therapeutic agents for cancer and preclinical studies of approved therapeutics. Those includes identification of new genes that are specifically expressed in cancer, targeted therapy of cancer, the immunotherapy, and the study of small molecule and protein drugs. In this special issue of OBM Genetics, we aim to the introduction of the latest research progress and novel models and technologies in molecular cancer therapeutics. There is no limitation on the article types, original research papers, reviews, editorial, short communications, case reports and perspectives are welcome for submission. We sincerely welcome authors in this field to contribute their excellent works to this exciting forum.
Title: Antibody-drug conjugates to treat negative breast cancer
Author: X. Margaret Liu
Title: Cardiomyocytes and the changes of the fuctionally determined spatial organization of ryanodin receptors during tumorgenesis
Author: Michael Hausmann
Title: IGF2 in physiology, cancer and cancer treatment
Author: Karoly Szuhai
Title: Clinical and molecular characteristics of biliary tract carcinoma using next-generation sequencing
Author: Antonio Cubillo Gracian
Title: Current progress on cancer immunotherapies using small molecules targeting PD-L1 stability
Author: Xiaolong Yang
Title: Interplay of Oncogenes and Their Immunosuppression in Gastric Cancer
Authors: Jiankang Jin, Xiaodan Yao, Shumei Song* and Jaffer A. Ajani*
Title: The use of Molecular techniques in diagnosis and therapy for patients
Author: Lampri Evangeli, et al
Title: A study on some calixpyrrole derivatives as potential cancer drugs
Authors: Franz Heinrich Kohnke, Camillo Rosano
Kwang Poo Chang, Dennis K. P. Ng, Chia-Kwung Fan, Ramesh B. Batchu, Bala K. Kolli
Received: December 29, 2019; Published: February 24, 2020; doi:10.21926/obm.genet.2001103
Bas T Röttgering, Karoly Szuhai
Received: May 14, 2019; Published: October 14, 2019; doi:10.21926/obm.genet.1904096
Caymen M. Novak, Eric N. Horst, Shreya Raghavan, Geeta Mehta
Received: June 17, 2019; Published: September 6, 2019; doi:10.21926/obm.genet.1903092
Tahereh Fatemian, Ezharul Hoque Chowdhury
Received: March 29, 2019; Published: August 15, 2019; doi:10.21926/obm.genet.1903090
Jennie Cao, Valentina L Kouznetsova, Igor F Tsigelny
Received: January 30, 2019; Published: April 1, 2019; doi:10.21926/obm.genet.1902071